Trial
NCT05525247
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Selecxine
Collaborators
—
Condition
Advanced Solid Tumor
Intervention
SLC-3010
Why stopped
Business decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-02